Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
Ascendis Pharma reported positive Week 78 data from the Phase 2 COACH trial, where the combination therapy of TransCon CNP and TransCon hGH achieved unprecedented annualized growth velocity of 7.73 cm/year in treatment-naïve patients, with 100% of enrolled children completing 78 weeks of treatment. Commercial uptake of YUVIWEL continues to gain momentum, reaching over 170 unique patient enrollments in the U.S. with more than 65% approved for reimbursement as of June 30, while a European regulatory decision is anticipated in the fourth quarter of 2026.
Key figures
- Drug Name
- TransCon CNP (navepegritide)
- Phase Of Trial
- Phase 2
- Attach trial retention rate
- 96%
- Eu regulatory decision timing
- Q4 2026
- Yuvwel us patient enrollments
- >170
- Yuvwel reimbursement approval rate
- >65%
- Coach week78 agv naive cohort cm per year
- 7.73
- Coach week78 agv experienced cohort cm per year
- 7.67
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.